spec sheet7 rows
Adarigiline is an investigational monoamine oxidase B (MAO-B) inhibitor first described in a 2009 patent assigned to Helicon Therapeutics. It was never advanced to marketing and public pharmacology data remain sparse.
- No confirmed human benefits; mechanism suggests potential relevance to Parkinson's disease research
Overview
Basically a patent-only compound; there just isn't much published on it beyond the chemistry filing.
Mechanism
Adarigiline is described as a selective inhibitor of monoamine oxidase B (MAO-B), the enzyme that breaks down and other monoamines in the brain. Blocking MAO-B is expected to raise dopamine levels, the same rationale behind approved MAO-B inhibitors used in Parkinson's disease.
receptor fingerprint
Monoamine oxidase B (MAO-B)Inhibitor
Safetyrisks and cautions, not medical advice
No clinical safety or tolerability data have been published; the compound never progressed beyond a 2009 composition-of-matter patent, so its human safety profile is unknown.
Subjective profileweighing the evidence above
A name on a 2009 patent and little else. There is no human pharmacology, no dosing and no safety record; the mechanism is plausible and everything downstream of it is unknown. Not something anyone can act on.
Resources
This entry is here for reference.
Reviews
My notesprivate to this device
FAQ
What is Adarigiline used for?
Adarigiline is not an approved or marketed drug. It is an investigational MAO-B inhibitor that was described in a 2009 patent and never progressed into published clinical development.
How does Adarigiline work?
It is designed to inhibit monoamine oxidase B, the enzyme that metabolizes dopamine, which would be expected to increase dopamine availability in the brain.
Is Adarigiline well-researched?
No. Available information is limited to a patent filing and chemical registries; there is no published pharmacology or clinical trial data.
Limitations of the evidence
- Unknown; no published human safety data